Human metabolism of [14C]indisulam following i.v. infusion in cancer patients

Investigational New Drugs

Volumn 23, Issue 4, 2005, Pages 317-330

  Beumer, Jan Hendrik ^a   Hillebrand, Michel J X ^a   Pluim, Dick ^a   Rosing, Hilde ^a   Foley, Karen ^b   Yule, S Murray ^b   Schellens, Jan H M ^a,c   Beijnen, Jos H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EISAI CO LTD   (Japan)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer; Indisulam; Metabolism; Pharmacokinetics; Radiochromatography

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; INDISULAM C 14; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER PATIENT; CHROMATOGRAPHY; DECHLORINATION; DRUG METABOLISM; DRUG STRUCTURE; GLUCURONIDATION; HUMAN; HYDROLYSIS; HYDROXYLATION; METABOLISM; OXIDATION; PRIORITY JOURNAL; SEPARATION TECHNIQUE; STRUCTURE ANALYSIS; SULFATION; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 22144492896     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-1440-4     Document Type: Article

References (22)

1. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, Kitoh K: Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42: 3789-3799, 1999
2. Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K: E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 37: 2275-2282, 2001
3. Van Kesteren C, Beijnen JH, Schellens JHM: E7070: A novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs 13: 989-997, 2002
4. Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T, Narita N, Saijo N, Nishio K: Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 19: 219-227, 2001
5. Yokoi A, Kuromitsu J, Kawai T, Nagasu T, Sugi NH, Yoshimatsu K, Yoshino H, Owa T: Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther 1: 275-286, 2002
6. Supuran CT: Indisulam: An anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 12: 283-287, 2003
7. Van den Bongard HJGD, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravie M, Schellens JHM, Beijnen JH: An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drugs 13: 807-814, 2002
8. Gillam EM, Notley LM, Cai H, De Voss JJ, Guengerich FP: Oxidation of indole by cytochrome P450 enzymes. Biochemistry 39: 13817-13824, 2000
9. Clapp JW: A new metabolic pathway for a sulfonamide group. J Biol Chem 223: 207-214, 1956
10. Mantle D, Preedy VR: Free radicals as mediators of alcohol toxicity. Adverse Drug React Toxicol Rev 18: 235-252, 1999
11. Morio M, Yuge O, Fujii K: Biotransformation and toxicity of inhalational anaesthetics. Can J Anaesth 37: Scxvi-Scxxiii, 1990
12. Bray TM, Kirkland JB: The metabolic basis of 3-methylindole-induced pneumotoxicity. Pharmacol Ther 46: 105-118, 1990
13. Poli G: Liver damage due to free radicals. Br Med Bull 49: 604-620, 1993
14. Koeplinger KA, Zhao Z, Peterson T, Leone JW, Schwende FS, Heinrikson RL, Tomasselli AG: Activated sulfonamides are cleaved by glutathione-S-transferases. Drug Metab Dispos 27: 986-991, 1999
15. Zhao Z, Koeplinger KA, Peterson T, Conradi RA, Burton PS, Suarato A, Heinrikson RL, Tomasselli AG: Mechanism, structure-activity studies, and potential applications of glutathione S-transferase-catalyzed cleavage of sulfonamides. Drug Metab Dispos 27: 992-998, 1999
16. Conroy CW, Schwam H, Maren TH: The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metab Dispos 12: 614-618, 1984
17. Klagkou K, Pullen F, Harrison M, Organ A, Firth A, Langley GJ: Fragmentation pathways of sulphonamides under electrospray tandem mass spectrometric conditions. Rapid Commun Mass Spectrom 17: 2373-2379, 2003
18. Barrientos-Astigarraga RE, Vannuchi YB, Sucupira M, Moreno RA, Muscara MN, De Nucci G: Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies. J Mass Spectrom 36: 1281-1286, 2001
19. Crommentuyn KM, Rosing H, Hillebrand MJ, Huitema AD, Beijnen JH: Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 804: 359-367, 2004
20. Clarke SJ, Beale PJ, Rivory LP: Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 39: 429-443, 2000
21. Rowland M, Tozer TN: Clinical Pharmacokinetics - Concepts and Applications. Williams & Wilkins, 1995
22. Van Kesteren C, Mathot RA, Raymond E, Armand JP, Dittrich C, Dumez H, Roche H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM: Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: Model building and validation. J Clin Oncol 20: 4065-4073, 2002